Douglas C. Bates

MMC Ventures Ltd.(MMC Ventures) is a venture capital firm founded in 2000 by Bruce Ferguson MacFarlane and Alan William Morgan. The firm is headquartered in London.

IPGL Ltd (IPGL) is a private equity firm founded in 1986. The firm is headquartered in London.

Sheffield Haworth Ltd. engages in the provision of recruitment services. It offers executive search, human capital research and advisory, and performance consulting services. The company was founded by Timothy Sheffield, Nigel Haworth and Patrick Morrissey in 1993 and is headquartered in London, the United Kingdom.

DDCAP Ltd. provides intermediary services to both conventional and Islamic financial market participants. Its services include liquidity management, syndicated financing, fund management, structured transactions, structures trade financing, and capital markets. The company was founded in 1998 and is headquartered in London, the United Kingdom.

CG Asset Management Ltd. (CGAM) is an independent, Great Britain-based fund manager which was founded in 2000. Headquartered in London, CGAM provides investment advice to institutional and professional clients.

Part of Evotec SE, Cyprotex US LLC is a company that provides contract research services specializing in preclinical ADME and Toxicology assessment. The company is based in Watertown, MA. Cyprotex US was acquired by Cyprotex Ltd., part of Evotec SE from December 15, 2016 on August 06, 2010 for $4.22 million. The company was founded by Douglas C. Bates, Katherine Tsaioun.

BioTek Instruments LLC provides microplate instrumentation and software for the drug discovery, genomics and proteomics and life science research fields. Its products include automated microplate detection systems for absorbance, fluorescence and chemiluminescence measurements, along with a complete line of automated washers, dispensers and pipetting systems, microplate stackers and robots, and data analysis software. BioTek Instruments was founded by Norman Alpert in 1968 and id headquartered in Winooski, VT.

The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr.